 HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 GLOBE NEWSWIRE -- Nymox Pharmaceutical Corporation NASDAQ: NYMX is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate FT, Nymoxs first in class lead product for the treatment of benign prostatic hyperplasia BPH. Substantial progress has been made and there are no material changes to the content of the planned applications. 